Children with cancer are only eligible for phase I clinical trials (P1Ts) when no known curative therapy remains. However, the primary aims of P1Ts are not focused on directly benefiting participants. This raises ethical concerns that can be best evaluated by exploring the experiences of participants. An empirical phenomenology study, using an adapted Colaizzi method, was conducted of 11 parents' lived experiences of their child's participation in a pediatric oncology P1T. Study findings were that parents' experiences reflected what it meant to have a child fighting to survive high-risk cancer. Although elements specific to P1T participation were identified, more pervasive was parents' sense of running out of time to find an effective treatment and needing to use time they had with their child well. Even though some problems were identified, overall parents did not regret their child's P1T participation and would recommend P1Ts to other parents of children with cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167192 | PMC |
| http://dx.doi.org/10.1177/1049732318766513 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Recent Increase in Invasive Bacterial Infections: A Report From the National COVID Cohort Collaborative.
Pediatr Infect Dis J
October 2024
From the Section of Critical Care Medicine, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado.
Background: When coronavirus disease 2019 (COVID-19) mitigation efforts waned, viral respiratory infections (VRIs) surged, potentially increasing the risk of postviral invasive bacterial infections (IBIs). We sought to evaluate the change in epidemiology and relationships between specific VRIs and IBIs [complicated pneumonia, complicated sinusitis and invasive group A streptococcus (iGAS)] over time using the National COVID Cohort Collaborative (N3C) dataset.
Methods: We performed a secondary analysis of all prospectively collected pediatric (<19 years old) and adult encounters at 58 N3C institutions, stratified by era: pre-pandemic (January 1, 2018, to February 28, 2020) versus pandemic (March 1, 2020, to June 1, 2023).
Development and validation of a novel immune-related prognostic model and the potential metastatic mechanism in synovial sarcoma.
Front Immunol
December 2024
State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Background: Several clinical trials have shown that immunotherapy plays a pivotal role in the treatment of patients with metastatic synovial sarcoma. Immune-related genes (IRGs) have been demonstrated to predict the immunotherapy response in certain malignant tumours. However, the clinical significance of IRGs in patients with synovial sarcoma (SS) is still unclear.
View Article and Find Full Text PDFRetinoblastoma in Ethiopian Children: Imaging Findings and Staging.
Ethiop J Health Sci
October 2024
Radiologists, Addis Ababa University, College of Health Sciences, Medical Faculty, Department of Radiology, Addis Ababa, Ethiopia.
Background: Retinoblastoma is the most prevalent intraocular retinal malignancy in children worldwide. Accurate staging is critical for treatment planning and relies heavily on radiologic imaging and clinical findings. This study aims to evaluate imaging patterns and staging of retinoblastoma in children at Tikur Anbessa Specialized Hospital (TASH).
View Article and Find Full Text PDFEfficacy of Submandibular Gland Excision Versus Preservation During Supraomohyoid Neck Dissection for T1, T2, and N0 Oral Squamous Cell Carcinoma.
Cureus
November 2024
General Surgery and Pediatric Surgery, Kalinga Institute of Medical Sciences, Kalinga Institute of Industrial Technology (Deemed to be University), Bhubaneswar, IND.
Introduction: The present study aims to observe the efficacy of submandibular gland excision vs. preservation during supraomohyoid neck dissection (SOHND) based on the postoperative outcomes for early oral squamous cell carcinoma (OSCC) with clinically N0 neck and xerostomia.
Materials And Methods: A pilot study was conducted to observe the efficacy of preservation vs.
Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia.
Pharmacotherapy
December 2024
Texas Children's Cancer and Hematology Centers, Houston, Texas, USA.
Background: Methotrexate is an important component of curative therapy in childhood acute lymphoblastic leukemia (ALL), but the role of genetic variation influencing methotrexate clearance and transport in toxicity susceptibility in children with ALL is not well established. Therefore, we evaluated the association between suspected methotrexate pharmacogenomic variants and methotrexate-related neurotoxicity.
Methods: This study included children (aged 2-20 years) diagnosed with ALL (2005-2019) at six treatment centers in the southwest United States.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!